Company
SGX:A50
Operator of private hospitals and clinics, with the group's distinctive concentration in women's health, fertility and maternity care. Its Singapore assets include Thomson Medical Centre and a network of women's clinics, fertility/IVF services and paediatric centres; it also operates in Malaysia (Thomson Hospital Kota Damansara) and Vietnam (FV Hospital, acquired 2023). The longevity-relevant limb is reproductive ageing: IVF and fertility treatment address declining ovarian reserve and age-related fertility loss in an ageing, low-birth-rate region. This is clinical service delivery, not geroscience research; the group does not develop ageing-directed therapeutics or biomarkers. Inclusion is on listing and HQ grounds (SGX-listed, Singapore-headquartered), with fertility as the thematic tie rather than any lifespan or healthspan intervention.
Thesis
Market data
| Metric | Detail |
|---|---|
| Exchange | SGX |
| Ticker | SGX:A50 |
| Secondary listing | None |
| Market cap | Not disclosed |
| Status | Listed and trading |
Get in touch
Offering
No commercial services are recorded for this company yet.
Recent inflection
Board and financial reset in early 2026: Tong Kooi Ong was appointed Independent Non-Executive Chairman effective 1 February 2026, succeeding Ng Ser Miang, in a move linked to the group's capital-intensive Johor Bay development in the Johor-Singapore Special Economic Zone. H1 2026 revenue rose to S$215.9m from S$201.9m a year earlier, with the net loss narrowing to S$10.2m, following an FY2025 loss driven by interest expense on the FV Hospital (Vietnam) acquisition and weaker Malaysian performance. (Reported via Simply Wall St; not independently confirmed against the SGX filing.)
Keep reading
Sources
Every entity profile on variis is sourced. Not investment advice.